MetaCap

Oramed Pharmaceuticals (ORMP) vs ProQR Therapeutics N.V. (PRQR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Oramed Pharmaceuticals (ORMP) has outperformed ProQR Therapeutics N.V. (PRQR) over the past year, gaining 38.4% versus a loss of 49.5%. Over five years, ORMP leads with a -82.3% price change compared with -85.5% for PRQR. Oramed Pharmaceuticals is the larger company by market cap ($155.2 million vs $147.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ORMP+38.37%PRQR-49.51%
+115%+29%-57%
Nov 21, 20251 yearNov 20, 2026
ORMP-86.53%PRQR-86.62%
+10%-44%-98%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ORMP versus PRQR key metrics
MetricORMPPRQR
Share price$3.57$1.04
Market cap$155.24M$146.98M
1-day change-3.25%-0.95%
YTD return+25.26%-48.51%
1-year return+38.37%-49.51%
5-year return-82.34%-85.54%
P/E ratio (TTM)1.05—
EPS (TTM)$3.41$-0.43
Dividend yield7.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$2.00M—
Net income (latest FY)$64.05M—
Gross margin0.65%—
Operating margin-754.40%—
Net margin3202.50%—
52-week high$5.47$2.49
52-week low$2.52$1.00
Distance from 52-week high-34.73%-58.15%
Analyst consensusnonestrong_buy
Avg. price target upside+96.08%+626.92%
Average volume173.38K793.64K
Shares outstanding43.49M141.33M
Employees—186
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ORMP has outperformed PRQR by 87.9 percentage points over the past year.
  • Oramed Pharmaceuticals offers a meaningfully higher dividend yield (7.00% vs 0.00%).

About Oramed Pharmaceuticals

ORMP stock →

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.

Health Care · Biotechnology: Pharmaceutical Preparations

About ProQR Therapeutics N.V.

PRQR stock →

ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs.

Health Care · Biotechnology: Pharmaceutical Preparations · 186 employees

ORMP vs PRQR FAQ

Which is bigger, Oramed Pharmaceuticals or ProQR Therapeutics N.V.?

Oramed Pharmaceuticals (ORMP) is larger, with a market capitalization of $155.24M compared with $146.98M for ProQR Therapeutics N.V. (PRQR).

Which stock has performed better over the past year, ORMP or PRQR?

ORMP returned +38.37% over the past 12 months, compared with -49.51% for PRQR (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, Oramed Pharmaceuticals or ProQR Therapeutics N.V.?

Oramed Pharmaceuticals pays a dividend yielding 7.00%, while ProQR Therapeutics N.V. does not currently pay a regular dividend.

Are Oramed Pharmaceuticals and ProQR Therapeutics N.V. in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons